|
* ¸ðµç ÀÏÁ¤ÀÇ Á¦¸ñÀº ÃßÈÄ º¯°æÀ̳ª Á¶Á¤ °¡´É ÇÔ
* ÀϽà : 2004³â 10¿ù 14ÀÏ(¸ñ) - 15ÀÏ(±Ý)
* Àå ¼Ò : ±×·£µåÈúư È£ÅÚ (È«Á¦µ¿ ¼ÒÀç)
2003 ³â 10 ¿ù 13 ÀÏ ( ¼ö )
| |
Á¦1ȸÀÇÀå |
Á¦2ȸÀÇÀå |
Á¦3ȸÀÇÀå |
Á¦4ȸÀÇÀå |
Á¦5ȸÀÇÀå |
Á¦6ȸÀÇÀå |
Á¦7ȸÀÇÀå |
¿¡¸Þ¶öµåB |
|
| 18:00-19:30 |
Satellite Symposium1 Çѹ̾àǰ ³ë¿µ¹«,½ÅÀÍ±Õ |
Satellite Symposium2 ´ë¿õÁ¦¾à ÃÖÀ±½Ä,Á¤³²½Ä |
|
|
|
|
|
|
2004 ³â 10 ¿ù 14 ÀÏ ( ¸ñ )
* 07:30 - 08:30 Á¤±â ÆòÀÇ¿øÈ¸ (Çöó¹Ö°í, º»°ü 2Ãþ)
| |
Á¦1ȸÀÇÀå |
Á¦2ȸÀÇÀå |
Á¦3ȸÀÇÀå |
Á¦4ȸÀÇÀå |
Á¦5ȸÀÇÀå |
Á¦6ȸÀÇÀå |
Á¦7ȸÀÇÀå |
¿¡¸Þ¶öµåB |
|
| 08:30-10:00 |
½ÉÆ÷Áö¿ò 1 -CAD- ¹Ú¿µ¹è,¹Ú½ÂÁ¤ |
½ÉÆ÷Áö¿ò 2 -Basic- ÀÌ¸í¹¬,Á¶¸íÂù |
½ÉÆ÷Áö¿ò 3 -HTN- À̹æÇå,Àå°æ½Ä |
Arrhythmia(1)
55-59 ¿¬±¸ºñ
ÃÖÀ±½Ä,½Åµ¿±¸
60-62 ¿¬±¸ºñ
È«¼øÁ¶,±è¿µÈÆ |
Heart Failure
73-76 ¿¬±¸ºñ
±èÇö½Â,½Å±æÀÚ
77-80 ¿¬±¸ºñ
½ÉºÀ¼·,±èÀçÁß |
Clinical Cardiology
91-95
ÀÌ¿ìÇü,À̰ÇÁÖ
96-99
¹®¾ð¼ö,À±È£Áß |
Congenital and Pediatric Disease(1)
123-126
±èöȣ,¹Ú¿µÈ¯
127-130
ÀÌÈïÀç,ÁÖÂù¿õ |
Æ÷½ºÅÍ ¹ßÇ¥(1)
(09:00 ~13:00)
1-80
|
| 10:00-10:30 |
ÈÞ ½Ä |
| 10:30-12:30 |
ÀþÀº ¿¬±¸ÀÚ»ó(1)
1-5
¹ÚÀÇÇö,·ù¿Õ¼º |
ÀþÀº ¿¬±¸ÀÚ»ó(2)
6-10
Á¤³²½Ä,È«°æÇ¥ |
Clinical Award Session(1)
1-6
ÀÌ¿ø·Î,¹Ú¼º¿í |
Clinical Award Session(2)
7-12
³ë¿µ¹«,¼ÛÀç°ü |
Clinical Award Session(3)
13-18
±è¼º¼ø,ÀÓÅÂȯ |
CAD(1)
100-103
°Á¤Ã¤,±èÁ¾Áø
104-107
Á¶½Â¿¬,¾ÈÅÂÈÆ
108-112
½É¿øÈì,¹Ú½ÃÈÆ
|
½ÉÆ÷Áö¿ò 7 -¼Ò¾Æ- ÀÌ»ó¹ü |
| 12:30-14:00 |
Satellite Symposium 3 Çѱ¹³ë¹ÙƼ½º ÀÌ¿ø·Î,ÀÓÁ¾À± |
Satellite Symposium 4 Çѱ¹ MSD ÀÌ ¿µ,¹èÁ¾È |
Satellite Symposium 5 º¸·ÉÁ¦¾à ÃÖ±Ôº¸,ÃÖ°æÈÆ |
Satellite Symposium 6 »ç³ëÇÇ- ½Åµ¥¶óº¸ ¹ÚÀÇÇö,À强±¹ |
Satellite Symposium 7 Çѵ¶¾Æº¥Æ¼½º ±èÁ¾¼º,±Ç¿µÁÖ |
|
|
| 14:00-15:30 |
CAD(2)
1-5
±Ç¿µÁÖ,¹Ú¼º¿í
6-9
±èÀçÇü,½Â±â¹è |
CAD(3)
20-23
½ÅÀͱÕ,ʽÂÁ¦
24-27
¿Àµ¿ÁÖ,Àå¾ç¼ö |
Basic(1)
38-41 ¿¬±¸ºñ
Á¶¸íÂù,±è¿µ±Ç
42-45 ¿¬±¸ºñ
ÀüÀº¼®,Á¤À͸ð |
½ÉÆ÷Áö¿ò 4 -CHF- ¿Àº´Èñ,ÀÌ»óÈÆ |
½ÉÆ÷Áö¿ò 5 -Imaging- ¹ÚÀçÇü,¹üÈñ½Â |
½ÉÆ÷Áö¿ò 6 Atherosc-lerosis ¹ÚÁ¤ÀÇ,±èÈ¿¼ö |
¼Ò¾Æ°ú ½ÉÆ÷Áö¿ò 8 -¼Ò¾Æ- ¹ÚÀμ÷,±è¿ëÁø |
Æ÷½ºÅÍ ¹ßÇ¥(2)
(14:00 ~18:00)
81-160
|
| 15:30-16:00 |
ÈÞ ½Ä |
| 16:00-18:00 |
CAD(4)
10-14
¿Àµ¿ÁÖ,Á¤¿í¼º
15-19
±è¿µÁ¶,±è¼ø±æ |
Aorta /Vascular /Others
28-32
ÃÖ¼®±¸,¼ÛÀç°ü
33-37
È«¼øÇ¥,±è¿øÈ£ |
Basic(2)
46-49 ¿¬±¸ºñ
±èö¹Î,¹Úâ±Ô
50-54 ¿¬±¸ºñ
½ÅÇöÈ£,°í±¤°ï |
Arrhythmia(2)
63-68
±è¼º¼ø,±è±âºÀ
69-72
±èÀ¯È£,Á¶Á¤°ü |
Diagnostic Imaging
81-85
À̵¿¼ö,ÃÖ¿¬Çö
86-90
ÀÓÅÂȯ,ÀÌÀçÅ |
HTN
113-117 ¿¬±¸ºñ
¹ÚÁ¾ÈÆ,±èöȣ
118-122 ¿¬±¸ºñ
±èÀçÇü,¹ÚÁ¤¹è |
Congenital and Pediatric Disease(2)
131-136
À±¿ë¼ö,¼º½ÃÂù
137-141
±è¼ºÈ£,±è³²¼ö |
| 18:00-19:00 |
Satellite Symposium 8 ¾Æ½ºÆ®¶ó- Á¦³×Ä« ¿Àº´Èñ,±è±â½Ä |
Satellite Symposium 9 GSK ¹Ú¿µ¹è,È«¼øÇ¥ |
Satellite Symposium 10 Çѱ¹ÈÀÌÀÚ ±è¼º¼ø,ÀÌÀç¿ì |
|
|
|
|
|
2004 ³â 10¿ù 15ÀÏ ( ±Ý )
| |
Á¦1ȸÀÇÀå |
Á¦2ȸÀÇÀå |
Á¦3ȸÀÇÀå |
Á¦4ȸÀÇÀå |
Á¦5ȸÀÇÀå |
Á¦6ȸÀÇÀå |
Á¦7ȸÀÇÀå |
¿¡¸Þ¶öµåB |
|
| 08:00-09:00 |
Morning Conference -CAD- ±è¿µÁ¶,½Â±â¹è |
Morning Conference -Echo- ¼Õ´ë¿ø,½É¿ÏÁÖ |
Morning Conference -CHF- À¯±ÔÇü,ÀüÀº¼® |
Morning Conference -Arrhythmia- ³ëÅÂÈ£,±èÀ±³â |
Morning Conference -Imaging- ÀÓÅÂȯ,¹®´ëÇõ |
Morning Conference -Basic- ¼È«¼®,±è´ö°æ |
Congenital and Pediatric Disease(3)
293-297 ¿¬±¸ºñ
±ÇÅÂÂù,°íÀç°ï
|
|
| 09:00-11:00 |
CAD(5)
142-147
ÀüÀçÀº,±ÇÇöö
148-153
È«ÅÃÁ¾,Çö¹Î¼ö
|
Echo(1)
167-171
¹Ú¼ºÈÆ,È«°æ¼ø
172-176
¹èÁ¾È,Á¤Áø¿ø
|
CAD(6)
191-195
¹ÚÁ¤·Î,È«¸í±â
196-200
±è¼º±¸,ÀÌöȯ
|
Arrhythmia(3)
215-219
¿Àµ¿Áø,À̸í¿ë
220-224
ÃÖÀμ®,±èÁؼö
|
CAD(7)
238-242
¼ºÀÎȯ,ÇѱԷÏ
243-248
¾çÁÖ¿µ,Â÷µ¿ÈÆ
|
Basic(3)
262-266
±è´ö°æ,ÁÖ½ÂÀç
267-270 ¿¬±¸ºñ
¼È«¼®,ÃÖµ¿ÁÖ
|
½ÉÆ÷Áö¿ò 11 -¼Ò¾Æ- ¸¶Àç¼÷,¼µ¿¸¸ |
Æ÷½ºÅÍ ¹ßÇ¥(3)
(09:00 ~13:00)
161-238
|
| 11:00-11:20 |
ÈÞ ½Ä |
| 11:20-12:00 |
Ư ° (ÃÖ±Ôº¸)
- Arterial Stiffening with Age : Cause, Consequence, Measurement and Therapy -
|
| 12:00-13:30 |
ÃÑ È¸ (Á¡ ½É) |
| 13:30-15:00 |
¿¬ ¼ö ° Á - Debate in the Management of Coronary Artery Diseases - ¹ÚÀÇÇö,Á¶½Â¿¬ |
½ÉÆ÷Áö¿ò 9 -Arrhythmia- ¼ÛÁ¤»ó,Á¶Á¤ÈÖ |
½ÉÆ÷Áö¿ò 10 -Echo- ½Å¿µ¿ì,ÀüÀçÀº |
Basic(4)
271-275
¹Ú¿µ¹è,¹é»óÈ«
276-279 ¿¬±¸ºñ
±èÈ¿¼ö,ÀÓµµ¼±
|
Congenital and Pediatric Disease(4)
298-301
ÃÖÁ¤¿¬,¼Õ¼¼Á¤
302-305
¼Õ⼺,³ëÁ¤ÀÏ
|
Æ÷½ºÅÍ ¹ßÇ¥(4)
(14:00 ~18:00)
239-306
|
| 15:00-15:30 |
ÈÞ ½Ä |
| 15:30-18:00 |
CAD(8)
154-159
¹Ú½ÂÁ¤,Á¤¸íÈ£
160-166
ÀÌ»óÈÆ,À±Á¤ÇÑ
|
Echo(2)
177-181
ÃÖ°æÈÆ,ÀüÈñ°æ
182-186
±è±Ç»ï,°´öÇö
187-190
±è±â½Ä,¹Ú½Â¿ì
|
VHD
201-205
À庴ö,Àå°æ½Ä
206-210 ¿¬±¸ºñ
¾ÈÇõ,¹ÚÁ¾Ãá
211-214
¹ÚÇ¥¿ø,±èµ¿¼ö
|
CAD(9)
225-230
±èÁ¤Çö,±è¹«Çö
231-237 ¿¬±¸ºñ
ÀÌÀç¿ì,ÃÖµ¿ÁÖ
|
CAD(10)
249-254
¹Ú±Ý¼ö,±è¿µ´ë
255-261
È«°æÇ¥,ȲÈï°ï
|
Basic(5)
280-285
¹ÚÁ¤ÀÇ,ÇѱâÈÆ
286-292
±èÄ¡Á¤,±èµ¿¿î
|
ÀÇ·á±â»ç ¿¬¼ö°ÁÂ
 |
2004³â Ãß°èÇмú´ëȸ ÀÏÁ¤
* ÀϽà : 2004³â 10¿ù 14ÀÏ(¸ñ) - 15ÀÏ(±Ý)
* Àå ¼Ò : ±×·£µåÈúư È£ÅÚ
¡á Ư° [10¿ù 15ÀÏ 11: 20 - 12:20 ]
¡á ¿¬¼ö°Á [10¿ù 15ÀÏ 13:30 - 15:00 ]
| Debate in the Management of Coronary Artery DiseasesÁÂÀå : ¹ÚÀÇÇö, Á¶½Â¿¬
|
|
|
1. Thrombolysis vs. PCI for AMI
|
|
|
2. PCI vs. CABG for 3 vessel disease
|
|
|
3. Noninvasive stress test & medical tx vs. direct CAG & PCI
|
¡á ½ÉÆ÷Áö¿ò
[ 10¿ù 14ÀÏ 08:30 - 10:00 ]
[ 10¿ù 14ÀÏ 14:00 - 15:30 ]
[ 10¿ù 14ÀÏ 10:30 - 12:30 ]
| 7. ¼Ò¾Æ : Valvular Heart DiseaseÁÂÀå : ÀÌ»ó¹ü |
| | ¿¬ÀÚ : Christian P Brizard / Royal Children's Hospital, Australia |
| | 1) Mitral valve surgery in pediatric patient, state of art |
| | 2) Ross procedure in pediatric patient |
[ 10¿ù 14ÀÏ 14:00 - 15:30 ]
[ 10¿ù 15ÀÏ 13:30 - 15:00 ]
[ 10¿ù 15ÀÏ 09:00 - 11:00 ]
¡á Morning Conference
[ 10¿ù 15ÀÏ 08:00 - 09:00 ]
¡á Satellite Symposium
[ 10¿ù 13ÀÏ 18:00 - 19:30 ]
[ 10¿ù 14ÀÏ 12:30 - 14:00 ]
| 3. Treatment of High Risk Hypertension Patients & VALUE ResultsÁÂÀå : ÀÌ¿ø·Î, ÀÓÁ¾À± |
| | 1) °íÀ§Ç豺 °íÇ÷¾Ð ȯÀÚ¿¡ ´ëÇÑ ÀÓ»óÀû Á¢±Ù - ¿¬¼¼ÀÇ´ë ÇÏÁ¾¿ø
|
| | 2) VALUE trial-its implication beyond BP control - ¼¿ïÀÇ´ë ÃÖµ¿ÁÖ
|
| 4. New Therapeutic Strategies to Optimize Treatment of Hypertension and Dyslipidemia ÁÂÀå : ÀÌ ¿µ, ¹èÁ¾È |
| | 1) Current practice in treatment of isolated systolic hypertension - °í·ÁÀÇ´ë ¹Úâ±Ô |
| | 2) Optimizing lipid management by dual inhibition - Claude R. Benedict / University of Texas Medical School, U.S.A
|
| 5. Arterial Stiffening, SNS, and CCB in HypertensionÁÂÀå : ÃÖ±Ôº¸, ÃÖ°æÈÆ |
| | 1) Vascular characteristics and antihypertensive therapy in hypertension - Michael O'Rourke / St. Vincent's Hospital, Australia |
| | 2) Effects of cilnidipine on sympathetic nervous system and arterial stiffness in essential hypertension - ¼º±Õ°ü ÀÇ´ë ¹ÚÁ¤¹è
|
| 6. ARBs and Cardioprotection; Potential Role of Irbesartan in the Management of Diastolic Heart Failure ÁÂÀå : ¹ÚÀÇÇö, À强±¹ |
| | Management of Diastolic Heart Failure Patients with Irbesartan - Henry Krum / Monash University, Australia
|
7. New Frontiers in Blockade of the Renin-angiotensin System - Ccardiovascular and Cerebrovascular ChallengesÁÂÀå : ±èÁ¾¼º,±Ç¿µÁÖ
|
| | Looking for a Better Antihypertensive Treatment to Effectively Prevent Cardiovascular Disease, Focus on Eprosartan - Alejandro de la Sierra / University of Barcelona, Spain
|
| | Cardiovascular Risk Reduction: The Importance of ACE Inhibition - Greg Conner / University of Sydney, Australia
|
[ 10¿ù 14ÀÏ 18:00 - 19:00 ]
|
|